Literature DB >> 19836263

Epilepsia partialis continua responsive to intravenous levetiracetam.

Carsten Eggers1, Lothar Burghaus, Gereon R Fink, Christian Dohmen.   

Abstract

We report on a case of epilepsia partialis continua with rapid response to intravenous bolus administration of levetiracetam. A 60-year-old woman presented with continuous jerking of the right foot and hallux persisting for more than two days. She had a 9-year history of epilepsy due to a left temporoparietal oligodendroglioma with occasional focal seizures clinically presenting as speech arrest, which was treated with levetiracetam and oxcarbazepine administered orally. After hospital admission, the twitching of the foot and toe was refractory to add-on treatment with lorazepam and diazepam but stopped within 15 min after intravenous bolus administration of 2000 mg levetiracetam. This observation suggests that intravenous bolus administration of levetiracetam may be an effective therapeutic option in epilepsia partialis continua.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19836263     DOI: 10.1016/j.seizure.2009.09.005

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  3 in total

1.  Epilepsia partialis continua following a Western variant tick-borne encephalitis.

Authors:  Lara Stragapede; Alessandro Dinoto; Marta Cheli; Paolo Manganotti
Journal:  J Neurovirol       Date:  2018-09-05       Impact factor: 2.643

2.  Levetiracetam induced encephalopathy in a patient with normal renal function: An unusual clinical encounter.

Authors:  Rajesh Verma; Rakesh Lalla; Tushar B Patil
Journal:  Ann Indian Acad Neurol       Date:  2013-10       Impact factor: 1.383

3.  Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy.

Authors:  Adriana Monserrath Orellana-Paucar; Tatiana Afrikanova; Joice Thomas; Yelaman K Aibuldinov; Wim Dehaen; Peter A M de Witte; Camila V Esguerra
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.